Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT04347252 · ClinicalTrials.gov registry record · Phase 1

Glucagon Regulation of Glucose Metabolism

A Phase 1 study, sponsored by David D'Alessio, M.D..

Completed
Registry status
Phase 1
Development phase
19
Enrollment target

NCT04347252 is a Phase 1 study that has completed, run by David D'Alessio, M.D.. The registered enrollment target is 19 participants.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT04347252, a Phase 1 study, has completed, sponsored by David D'Alessio, M.D..

COMPLETED
Registry status
Phase 1
Development phase
19 participants
Enrollment target

Study Summary

Glucagon is a 30 amino acid peptide hormone that is produced exclusively in alpha-cells of the pancreatic islets. Glucagon binds to a G-protein coupled receptor and activates intracellular signaling by increasing the synthesis of cyclic AMP by adenylate cyclase. The glucagon receptor is most prominently expressed by hepatocytes and the cardinal action of glucagon is to stimulate hepatic glucose output by increasing glycogenolysis and gluconeogenesis. A deep body of literature supports physiologic actions of glucagon to maintain fasting blood glucose and counter-regulate hypoglycemia, and the current view of glucose metabolism is that insulin and glucagon have opposing and mutually balancing effects on glycemia. However, it has long been appreciated that glucagon actually stimulates insulin secretion and islet β-cells express the glucagon receptor and respond to its activation by increasing cAMP. The most potent stimulus for glucagon release is hypoglycemia and both low glucose per sé, as well as sympathetic nervous system activity are potent activators of the alpha-cell. However, glucagon is also stimulated by elevations of circulating amino acids, including after protein containing meals; this setting is one in which the release of glucagon during a period of elevated glycemia could contribute to postprandial insulin secretion. In fact, we have demonstrated that normal mice injected with glucagon while fasting (BG 75 mg/dl) have a prompt rise in blood glucose, whereas mice given glucagon while feeding (BG 150 mg/dl) increase insulin output 3 fold and have a decrease in glycemia. Moreover, in studies with isolated mouse and human islets we have demonstrated that glucagon stimulates insulin release by activating both the glucagon and GLP-1 receptors. This counter-intuitive observation has been reported by several other groups as well as ours. In the studies proposed herein we wish to extend our novel observations to humans. The possibility that glucagon acts in the

Interventions

  • DRUG Glucagon

Trial Details

FieldValue
Enrollment Target 19 participants
Start Date 2019-09-24
Est. Completion 2021-04-16
Phase Phase 1

Sponsor

David D'Alessio, M.D.

4 total trials

What the Registry Record Tells You About NCT04347252

The ClinicalTrials.gov registry entry for NCT04347252 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 19 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is David D'Alessio, M.D., which has 4 total studies on file at ClinicalTrials.gov.

The record links to 0 conditions, and to 1 intervention - of which Glucagon is the first listed.

NCT04347252 reports 0 study locations.

Frequently Asked Questions

What is clinical trial NCT04347252 about?

NCT04347252 is a clinical study titled "Glucagon Regulation of Glucose Metabolism". Glucagon is a 30 amino acid peptide hormone that is produced exclusively in alpha-cells of the pancreatic islets. Glucagon binds to a G-protein coupled receptor and activates intracellular signaling by increasing the synthesis of cyclic AMP by adenylate cyclase. The glucagon receptor is most promine...

What is the current status of trial NCT04347252?

This trial is currently completed. It is a Phase 1 study. The enrollment target is 19 participants. The study started on 2019-09-24. Estimated completion is 2021-04-16.

What interventions are being tested in trial NCT04347252?

The interventions under investigation include: Glucagon (DRUG).

Who is sponsoring clinical trial NCT04347252?

This trial is sponsored by David D'Alessio, M.D., which has 4 total clinical trials registered on ClinicalTrials.gov.

Data sourced from official public datasets. See our methodology for details. Retrieved and formatted by PlainTrial Editorial

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.